Novo confirms Catalent Indiana plant has started filling Wegovy pens
Reuters
Published Jan 31, 2024 05:03AM ET
Updated Jan 31, 2024 05:25AM ET
LONDON/COPENHAGEN (Reuters) -Catalent's Indiana plant in the United States has started filling injection pens for Novo Nordisk (NYSE:NVO)'s obesity drug Wegovy, the Danish drugmaker's CEO told Reuters on Wednesday, helping to boost output of the popular weekly injection.
The comment by Lars Fruergaard Jorgensen is the first confirmation the site has started production.
Reuters reported last August that the plant in Bloomington, Indiana, was the third external site hired by Novo to do so-called "fill-finish" for Wegovy, as it scrambled to ramp up output due to soaring demand.
Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in November that plans were on track for the third site to start operating by the end of 2023, but would not identify the site.
Novo has hired another contract manufacturer, Thermo Fisher (NYSE:TMO), and has some in-house capacity for filling syringes and packaging its pens.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.